...
首页> 外文期刊>Stem Cell Research & Therapy >Therapeutic efficiency of human amniotic epithelial stem cell-derived functional hepatocyte-like cells in mice with acute hepatic failure
【24h】

Therapeutic efficiency of human amniotic epithelial stem cell-derived functional hepatocyte-like cells in mice with acute hepatic failure

机译:人羊膜上皮干细胞来源的功能性肝细胞样细胞对急性肝衰竭小鼠的治疗效率

获取原文
           

摘要

Hepatocyte transplantation has been proposed as an effective treatment for patients with acute liver failure (ALF), but its application is limited by a severe shortage of donor livers. Human pluripotent stem cells (hPSCs) have emerged as a potential cell source for regenerative medicine. Human amniotic epithelial stem cells (hAESCs) derived from amniotic membrane have multilineage differentiation potential which makes them suitable for possible application in hepatocyte regeneration and ALF treatment. The pluripotent characteristics, immunogenicity, and tumorigenicity of hAESCs were studied by various methods. hAESCs were differentiated to hepatocyte-like cells (HLCs) using a non-transgenic and three-step induction protocol. ALB secretion, urea production, periodic acid-Schiff staining, and ICG uptake were performed to investigate the function of HLCs. The HLCs were transplanted into ALF NOD-SCID (nonobese diabetic severe combined immunodeficient) mouse, and the therapeutic effects were determined via liver function test, histopathology, and survival rate analysis. The ability of HLCs to engraft the damaged liver was evaluated by detecting the presence of GFP-positive cells. hAESCs expressed various markers of embryonic stem cells, epithelial stem cells, and mesenchymal stem cells and have low immunogenicity and no tumorigenicity. hAESC-derived hepatocytes possess the similar functions of human primary hepatocytes (hPH) such as producing urea, secreting ALB, uptaking ICG, storing glycogen, and expressing CYP enzymes. HLC transplantation via the tail vein could engraft in live parenchymal, improve the liver function, and protect hepatic injury from CCl4-induced ALF in mice. More importantly, HLC transplantation was able to significantly prolong the survival of ALF mouse. We have established a rapid and efficient differentiation protocol that is able to successfully generate ample functional HLCs from hAESCs, in which the liver injuries and death rate of CCl4-induced ALF mouse can be significantly rescued by HLC transplantation. Therefore, our results may offer a superior approach for treating ALF.
机译:肝细胞移植已被提议作为急性肝衰竭(ALF)患者的有效治疗方法,但其应用受到供体肝脏严重短缺的限制。人多能干细胞(hPSC)已成为再生医学的潜在细胞来源。源自羊膜的人羊膜上皮干细胞(hAESC)具有多系分化潜能,使其适合可能在肝细胞再生和ALF治疗中应用。 hAESCs的多能特性,免疫原性和致瘤性已通过各种方法进行了研究。使用非转基因和三步诱导方案,将hAESCs分化为肝细胞样细胞(HLC)。进行ALB分泌,尿素生成,高碘酸-希夫(Schiff)染色和ICG摄取以研究HLC的功能。将HLCs移植到ALF NOD-SCID(非肥胖糖尿病严重合并免疫缺陷)小鼠中,并通过肝功能测试,组织病理学和存活率分析确定治疗效果。通过检测GFP阳性细胞的存在来评估HLCs植入受损肝脏的能力。 hAESCs表达了胚胎干细胞,上皮干细胞和间充质干细胞的各种标记,并且免疫原性低,没有致瘤性。 hAESC衍生的肝细胞具有与人类原代肝细胞(hPH)类似的功能,例如产生尿素,分泌ALB,吸收ICG,储存糖原和表达CYP酶。通过尾静脉进行的HLC移植可以植入活体实质中,改善肝脏功能,并保护小鼠免受CCl4诱导的ALF的肝损伤。更重要的是,HLC移植能够显着延长ALF小鼠的生存期。我们已经建立了一种快速有效的分化方案,该方案能够成功地从hAESC生成功能丰富的HLC,通过HLC移植可以显着挽救CCl4诱导的ALF小鼠的肝损伤和死亡率。因此,我们的结果可能为治疗ALF提供了一种更好的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号